MAGNISENSE SE aus Paris auf der MEDICA 2018 in Düsseldorf -- COMPAMED Messe

MAGNISENSE SE

16 avenue Hoche, 75008 Paris
Frankreich
Telefon +33 1 45628000
Fax +33 1 45620527
contact@magnisense.com

Dieser Aussteller ist Mitaussteller von
Business France SA

Hallenplan

MEDICA 2018 Hallenplan (Halle 3): Stand G64

Geländeplan

MEDICA 2018 Geländeplan: Halle 3

Unser Angebot

Produktkategorien

  • 03  Diagnostika
  • 03.02  Immunochemie / Immunologie
  • 03.02.02  Diagnose-Schnelltests

Diagnose-Schnelltests

Unsere Produkte

Produktkategorie: Diagnose-Schnelltests

Diagnostic rapid tests

MiAG® allows to perform a mobile diagnostic of cardiovascular disorders, in particular heart failure and heart attack, by quantifying specific cardiac biomarkers directly in a whole blood sample in only 15 minutes, in a decentralized way. MiAG® is composed of a mobile device and ready to use consumables and is reaching the specifications required by the central labs and physicians in emergency situations.
The tests are based on the MIAtek® technology, a breakthrough innovative technology that exploits magnetic nanoparticles properties. This unique technology is worldwide protected under several patents already delivered.

Mehr Weniger

Über uns

Firmenporträt

Magnisense is a private company which designs, develops and markets emergency diagnostic tests for cardiovascular diseases. Our mission is to improve the emergency medicine with three main goals: to save lives, to reduce patient’s disabilities by initiating the therapeutic management as soon as possible, and to contribute to reduce the healthcare costs associated to the diseases. Cardiovascular diseases are the first cause of mortality in the world.
After several years of research and development, the company is now entering the market with its MiAG® products.
MiAG® allows to perform a mobile diagnostic of cardiovascular disorders, in particular heart failure and heart attack, by quantifying specific cardiac biomarkers directly in a whole blood sample in only 15 minutes, in a decentralized way. MiAG® is composed of a mobile device and ready to use consumables and is reaching the specifications required by the central labs and physicians in emergency situations.
The tests are based on the MIAtek® technology, a breakthrough innovative technology that exploits magnetic nanoparticles properties. This unique technology is worldwide protected under several patents already delivered.
The company is headquartered in Paris while its R&D laboratory, “Le Campus,” is located at the heart of the Lyon science park, Lyonbiopôle.
Magnisense is focused on becoming a leader in emergency cardiac diagnostics by marketing competitive tests that address public health and economic issues. For more information, visit: www.magnisense.com

Mehr Weniger